The novel therapeutic agent PA65020 (enteric-coated aspirin plus immediate-release omeprazole) significantly reduced gastrointestinal mucosal damage after 28 days of treatment compared with enteric-coated aspirin (EC-ASA) alone. Results of this single-center, phase I, randomized, double-blind study suggest that for at-risk patients requiring analgesic doses of aspirin, PA65020 may be an important option according to a study presented at the 29th Annual ...
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.